Medication Review for SIBO: How to Talk to Your Doctor About Deprescribing

Identifying that a medication may be contributing to your SIBO is only the first step. The next step, and often the more challenging one, is having a productive conversation with your prescribing clinician about whether and how to make changes. This conversation requires preparation, specificity, and an understanding that not all medications can or should be stopped. Deprescribing is a structured, evidence-based process of reducing or discontinuing medications when the potential harms outweigh the benefits. For SIBO patients, a well-prepared medication review can identify modifiable risk factors that no amount of antimicrobial treatment can address.

How to prepare for a medication review

Preparation is the difference between a productive medication review and a frustrating appointment. Before your visit, create a complete medication list that includes every prescription medication (with dose and frequency), every over-the-counter medication (including PPIs, antihistamines, sleep aids, and antidiarrheals), and every supplement. For each medication, note when you started it, what it was prescribed for, and whether that condition is still active. This information may not be readily available in your medical record, especially if you have changed providers or health systems.

Which medications to prioritize reviewing

Not all medication reviews need to address every drug simultaneously. Prioritize based on the strength of the SIBO connection and the likelihood that the medication can be safely changed. PPIs are often the highest-priority target because the evidence linking them to SIBO is strong, an estimated 25-70% of long-term users lack a current indication, and well-established tapering protocols exist. Over-the-counter PPIs are particularly good candidates because they were often self-initiated without medical evaluation.

Anticholinergic medications are the next priority, particularly if you are taking multiple drugs with anticholinergic effects. Individually mild anticholinergic medications may not seem concerning, but their cumulative effect can meaningfully impair gut motility. A medication like diphenhydramine taken nightly for sleep, combined with oxybutynin for bladder symptoms and amitriptyline for neuropathy, creates substantial anticholinergic burden. Opioids are important to review but often more complex to change due to pain management considerations and the risk of withdrawal.

Safe tapering: PPIs

PPIs should never be stopped abruptly after long-term use. Rebound acid hypersecretion occurs when the compensatory increase in gastrin levels and parietal cell mass leads to excess acid production once the PPI is removed. This rebound can last 2 to 8 weeks and often causes symptoms worse than the original reason for the PPI, leading patients to restart the medication. A gradual taper prevents or minimizes rebound.

Safe tapering: opioids

Opioid tapering is medically complex and should always be supervised by the prescribing clinician, typically a pain management specialist or primary care provider experienced in opioid management. Abrupt opioid discontinuation after chronic use causes physical withdrawal symptoms (including rebound pain, anxiety, sweating, insomnia, diarrhea, and muscle aches) and is medically inappropriate. The CDC recommends a gradual taper of 10% of the total daily dose per month for patients who have been on chronic opioid therapy, though the rate can be adjusted based on individual response.

For SIBO management purposes, the goal may not be complete opioid discontinuation. Even a dose reduction can improve gut motility. Alternatively, discussing a switch to a non-opioid pain management approach (NSAIDs if appropriate, gabapentinoids, physical therapy, interventional procedures) may be more practical than opioid discontinuation. For patients who must remain on opioids, adding a prokinetic to compensate for motility suppression is a reasonable mitigation strategy, though the effectiveness of prokinetics against opioid-induced motility impairment has limits.

Alternatives to discuss with your prescriber

For each SIBO-promoting medication, there may be alternatives that provide similar therapeutic benefit with less gut impact. These alternatives are worth discussing even if they are not perfect substitutes. The goal is to find the option that best balances the treatment of the original condition with the minimization of SIBO risk.

When NOT to stop medications

Not every SIBO-promoting medication can or should be changed. Certain clinical situations require continued therapy despite the SIBO risk. PPIs for Barrett's esophagus, severe erosive esophagitis (LA grades C and D), or Zollinger-Ellison syndrome should be continued. Opioids for severe chronic pain when non-opioid alternatives have been exhausted or are contraindicated need to be maintained with SIBO management as an adjunct. Immunosuppressants for organ transplant rejection prevention or active autoimmune disease are medically essential. In these situations, the focus shifts from medication discontinuation to mitigation: adding prokinetics, optimizing meal spacing, monitoring for SIBO with periodic breath testing, and treating overgrowth promptly when it occurs.

Documenting for your doctor visit

Bring a written or printed document to your appointment that includes your complete medication list with doses, your SIBO diagnosis and treatment history, a list of medications you want to review with the reason for each (e.g., this medication is in a SIBO-promoting class), specific questions for each medication, and any relevant test results (breath tests, ibs-smart results). Having this prepared in advance ensures the conversation is focused and productive, especially given the time constraints of most medical appointments.